Interpace Diagnostics Group (NASDAQ: IDXG) and Brink’s Company (The) (NYSE:BCO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Interpace Diagnostics Group and Brink’s Company (The), as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interpace Diagnostics Group 0 0 0 0 N/A
Brink’s Company (The) 0 1 3 0 2.75

Brink’s Company (The) has a consensus target price of $62.00, indicating a potential downside of 18.47%. Given Brink’s Company (The)’s higher probable upside, analysts plainly believe Brink’s Company (The) is more favorable than Interpace Diagnostics Group.

Risk and Volatility

Interpace Diagnostics Group has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Brink’s Company (The) has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

Dividends

Brink’s Company (The) pays an annual dividend of $0.60 per share and has a dividend yield of 0.8%. Interpace Diagnostics Group does not pay a dividend. Brink’s Company (The) pays out 35.7% of its earnings in the form of a dividend.

Institutional & Insider Ownership

1.4% of Interpace Diagnostics Group shares are owned by institutional investors. Comparatively, 89.3% of Brink’s Company (The) shares are owned by institutional investors. 2.5% of Interpace Diagnostics Group shares are owned by company insiders. Comparatively, 10.4% of Brink’s Company (The) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Interpace Diagnostics Group and Brink’s Company (The)’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group $13.52 million 0.52 -$10.02 million N/A N/A
Brink’s Company (The) $3.15 billion 1.22 $340.80 million $1.68 45.27

Brink’s Company (The) has higher revenue and earnings than Interpace Diagnostics Group.

Profitability

This table compares Interpace Diagnostics Group and Brink’s Company (The)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group -37.14% -53.68% -11.80%
Brink’s Company (The) 2.73% 34.49% 6.56%

Summary

Brink’s Company (The) beats Interpace Diagnostics Group on 11 of the 13 factors compared between the two stocks.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

About Brink’s Company (The)

The Brink’s Company (Brink’s) is a provider of logistics and security solutions. The Company operates through nine segments: U.S., France, Mexico, Brazil, Canada, Latin America, EMEA, Asia and Payment Services. The Company’s solutions include cash-in-transit (CIT), automated teller machine (ATM) replenishment and maintenance, cash management services, including vault outsourcing, money processing, and intelligent safe services, international transportation of valuables, and payment services. Its customers include financial institutions, retailers, government agencies (including central banks), mints, jewelers and other commercial operations around the world. As of December 31, 2016, the Company’s global network served customers in over 100 countries. Its services offerings include Core Services, High-Value Services and Other Security Services.

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.